Do you hate to see your old used cell phone clogging your apartment? And you are looking to find out the best way to deal with it? Then you have come to the right doors. This website sellmymobile.com is the ultimate solution to deal with your old cell phones. Here you can find the best prizes for your used cell phones. There two benefits out of this process. One you earn money and at the same time you recycle the phone. This is something that you can do to the environment. This site helps to sell your mobile online. It is easy to have an access to the recyclers and the other companies. It is guaranteed that your phone will find the ultimate price. The site sellmymobile.com has an easy four way step to compare the value of your phone will all possible buyers. So you can choose to whom you would like to sell the phone. All the website that are meant for selling your mobile in here and can be very helpful. Just have a look at this site sellmymobile.com and have a clear idea about it. Kindly log on to the site sellmymobile.com to get the maximum out of it!! Cheers!!
Archive for category Technology
Sell My Mobile
Jul 23
Navigation Gps
Dec 15
Mio release Moov M400 and Moov M300 GPS navigation which is available now in United States.
The Mio Moov M400 has 4.3-inch touchscreen with price $149.99 and the Mio Moov M300 has 3.5-inch touchscreen display with price $199.99. Both of the Mio GPS featuring text-to-speech, lane Guidance, NavPix Photo Navigation and 4-million points of interest. Now it’s available with maps of all 50 US states and Puerto Rico.
Another sign today of stem cell research becoming more commercial: An announcement that Stephen Minger, one of the field’s leading academics, will join GE Healthcare next week as head of Research and Development for Cell Technologies.
Minger, an American, has been in charge of stem cell biology at Guy’s Hospital and King’s College London since moving to the UK in 1996.
As well as being one of the top researchers into human embryonic stem cells in Britain – his lab has derived several hESC lines including ones with genetic mutations for cystic fibrosis and Huntington’s disease – Minger has been a fearless public advocate of stem cell science.
The relatively science-friendly legislative and regulatory framework for embryo research that has emerged in the UK owes something to Minger’s communications skills. He is one of the most open and media-friendly scientists I have come across, in any field.
“Leading GE Healthcare’s Cell Technologies research and development will allow me to bring many years of academic research in the stem cell field to bear in a commercial environment,” he says. “This is an opportunity for me to play a leading role in the realization of the emerging potential of stem cell technology in drug discovery and therapy, and to help grow a strategic business for GE Healthcare.”
GE Healthcare, part of the giant US General Electric group, is one of the world’s largest and most broadly based medical technology companies. It made clear its corporate ambitions in stem cell research at the end of June when it announced an exclusive alliance with Geron, the leading US stem cell company. Minger will, among other duties, lead the GE side of the Geron partnership. He will be based in the UK.
GE’s role in the commercialisation of stem cells will be to provide a comprehensive range of cells and tools for research and development. It does not intend to produce its own treatments.
Incidentally Geron has commented further on last week’s decision by the US Food and Drug Administration to put “on hold” its application to carry out the world’s first clinical trial of a treatment based on embryonic stem cells. The product would treat spinal cord injury.
The California-based company says the FDA suspension relates to “microscopic cysts” that appeared on some animals during preclinical testing. Reassuringly, the cysts were not cancerous and had no adverse effects on the animals, so it seems likely that the clinical trial will go ahead soon.
“It is appropriate for the FDA to be particularly cautious about the first clinical trial of embryonic stem cells,” Minger says.